AUS
NZ
UK
CA
USA
IND
Emerging companies Lumos Diagnostics, Memphasys, and Vitura Health are making notable strides in their respective sectors. From advancing diagnostic technologies to revolutionizing fertility solutions and expanding telehealth services, these ASX healthcare stocks are positioned to impact their industries significantly. Here’s a closer look at their latest developments and market performance.
Lumos Diagnostics (ASX:LDX) is set to raise $10 million to support the expansion of its flagship product, FebriDx. This innovative finger-prick blood test can distinguish between viral and bacterial infections within just 10 minutes. The funding round involves Tenmile Ventures, an investment arm of Andrew and Nicola Forrest’s Tattarang, acquiring 45 million shares from Lumos’s founding shareholder, Planet Innovations. The non-renounceable rights offer allows investors to purchase shares at 3.8 cents each, representing a 17.4% discount to the previous closing price.
The capital raised will be used for general product development and to fund a Clinical Laboratory Improvement Amendment (CLIA) study in the United States. Securing a CLIA waiver would significantly expand the market for FebriDx, potentially increasing its addressable market to $1 billion annually. The test, approved in the US in mid-2023, could be administered in more health facilities without laboratory oversight if the waiver is granted. Lumos shares remained steady at 4.6 cents.
Memphasys (ASX:MEM) is making strides in equine fertility with its Felix sperm-selection device. The company aims to have Felix ready for the equine market within a year, targeting over 4,000 non-thoroughbred horse breeders. Memphasys has announced a three-year fertility study in collaboration with the University of Newcastle, EquiBreedUK Ltd, and local studs Arrowfield and Vinery.
Felix uses electrophoresis, a technique that separates sperm based on electrical charge, which is gentler and faster than traditional methods like density gradient centrifugation. This innovation addresses the need for efficient sperm selection, crucial for artificial insemination in both horses and humans. Memphasys is also conducting trials in collaboration with Monash IVF to compare Felix with conventional methods, aiming for regulatory approval from the Therapeutic Goods Administration. The device is already sold in Japan, where declining birth rates have heightened demand for effective fertility solutions. Memphasys shares held steady at 0.9 cents.
Vitura Health (ASX:VIT) is navigating a challenging landscape in the medical cannabis sector while expanding its telehealth services. Despite facing intense competition and falling margins in the cannabis market, Vitura reported a 5.6% revenue increase to $123.9 million for the current year. However, normalised net profit decreased by 75% to $4.8 million due to a 26.5% drop in gross margins.
Unlike traditional cannabis companies, Vitura does not cultivate cannabis but operates the Canview platform, which connects patients with over 15,000 prescribers across 60 third-party brands. The company has also diversified into general telehealth by acquiring Doctors on Demand in a $25 million deal last October. This expansion has proven successful, with consulting revenue from Doctors on Demand increasing by 874% to $15.4 million within the first eight weeks of ownership. Vitura Health continues to adapt and grow amidst market challenges.
These developments from Lumos Diagnostics, Memphasys, and Vitura Health highlight their strategic advancements and efforts to address market needs and capitalize on emerging opportunities in their respective fields.
